The Evaluation of the Effect of Herbal Extract on Osteoarthritis: In Vitro and In Vivo Study

  • Kim, Jaeyong (Jeonnam Institute of Natural Resources Research) ;
  • Yang, Siyoung (Korea Research Institute of Bioscience and Biotechnology) ;
  • Choi, Chul-yung (Jeonnam Institute of Natural Resources Research)
  • Received : 2016.09.27
  • Accepted : 2016.11.28
  • Published : 2016.12.31


In this study, the anti-osteoarthritis effects of Cynanchum wilfordii, Phlomis umbrosa, and Angelica gigas extract (CPAE), observed and confirmed in previously clinical studies were further investigated by in vitro and in vivo studies. Anabolic biomarkers related to healthy cartilage maintenance, such as aggrecan, type II collagen ${\alpha}$-1 (Col2a1), sex determining region Y-box-9 (Sox-9), and catabolic biomarkers related to osteoarthritis, such as cyclooxygenase-2 (Cox-2), matrix metalloproteinase-13 (Mmp13), and nuclear factor kappa-light-chain-enhancer of activated B cells ($Nf{\kappa}b$), were evaluated by quantitative reverse transcriptase polymerase chain reaction and reporter gene assay. In vitro study results showed significant changes in both anabolic and catabolic biomarkers. For anabolic factors, significant changes in the level of aggrecan (P<0.05), Col2a1 (P<0.05), and Sox-9 (P<0.01) activation were shown after treatment of cartilage cells with CPAE (50 ng/mL) with similar efficacy compared to insulin growth factor, the positive control (100 ng/mL). For catabolic factors, significant changes in the inhibition activity of Cox-2 (P<0.05), Mmp13 (P<0.01), and $Nf{\kappa}b$ (P<0.05) were shown for CPAE (50 ng/mL) with similar efficacy compared to Celecoxib, the positive control ($10{\mu}M$). In the in vivo carrageenan-induced paw edema model study results showed that CPAE-treated groups (100 mg/kg) and Celecoxib-treated groups (60 mg/kg) showed comparably significant efficacy of inhibition by 37.1% and 52.1%, respectively. Furthermore, CPAE (200 mg/kg) showed similar effect to Celecoxib (60 mg/kg) with an inhibition rate of 54.3%. This result confirms that CPAE effectively inhibited the inflammation-induced osteoarthritis symptoms.


Grant : Commercial Bio-technology Sophistication Platform Construction Program

Supported by : Creative Industry Institutes


  1. Elders MJ. 2000. The increasing impact of arthritis on public health. J Rheumatol Suppl 60: 6-8.
  2. Hoegh-Andersen P, Tanko LB, Andersen TL, undberg CV, Mo JA, Heegaard AM, Delaisse JM, Christgau S. 2004. Ovariectomized rats as a model of postmenopausal osteoarthritis: validation and application. Arthritis Res Ther 6: R169-R180.
  3. Sangha O. 2000. Epidemiology of rheumatic diseases. Rheumatology 39: 3-12.
  4. Hart DJ, Doyle DV, Spector TD. 1999. Incidence and risk factors for radiographic knee osteoarthritis in middle-aged women: the Chingford Study. Arthritis Rheum 42: 17-24.<17::AID-ANR2>3.0.CO;2-E
  5. Nevitt MC, Cummings SR, Lane NE, Hochberg MC, Scott JC, Pressman AR, Genant HK, Cauley JA. 1996. Association of estrogen replacement therapy with the risk of osteoarthritis of the hip in elderly white women. Arch Intern Med 156: 2073-2080.
  6. Spector TD, Campion GD. 1989. Generalised osteoarthritis: a hormonally mediated disease. Ann Rheum Dis 48: 523-527.
  7. Richette P, Corvol M, Bardin T. 2003. Estrogens, cartilage, and osteoarthritis. Joint Bone Spine 70: 257-262.
  8. Hannan MT, Felson DT, Anderson JJ, Naimark A, Kannel WB. 1990. Estrogen use and radiographic osteoarthritis of the knee in women. Arthritis Rheum 33: 525-532.
  9. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333.
  10. Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R. 2015. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 385: 1835-1842.
  11. Lee KH, Lee DJ, Kim SM, Je SH, Kim EK, Han HS, Han IK. 2005. Evaluation of effectiveness and safety of natural plants extract ($Estromon^{(R)}$) on perimenopausal women for 1 year. J Menopausal Med 11: 16-26.
  12. Chang A, Kwak BY, Yi K, Kim JS. 2012. The effect of herbal extract (EstroG-100) on pre-, peri- and post-menopausal women: a randomized double-blind, placebo-controlled study. Phytother Res 26: 510-516.
  13. Fraser A, Fearon U, Billinghurst RC, Ionescu M, Reece R, Barwick T, Emery P, Poole AR, Veale DJ. 2003. Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation. Arthritis Rheum 48: 3085-3095.
  14. Kim KI, Park YS, Im GI. 2013. Changes in the epigenetic status of the SOX-9 promoter in human osteoarthritic cartilage. J Bone Miner Res 28: 1050-1060.
  15. Yang S, Kim J, Ryu JH, Oh H, Chun CH, Kim BJ, Min BH, Chun JS. 2010. Hypoxia-inducible factor-$2{\alpha}$ is a catabolic regulator of osteoarthritic cartilage destruction. Nat Med 16: 687-693.
  16. Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S. 1994. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 47: 55-59.
  17. KFDA. 2012. Evaluation guide of functional activities for health functional food. Korea Food and Drug Administration, Chungbuk, Korea. p 37.
  18. Ikeuchi M, Kolker SJ, Sluka KA. 2009. Acid-sensing ion channel 3 expression in mouse knee joint afferents and effects of carrageenan-induced arthritis. J Pain 10: 336-342.
  19. Yang Y, Leech M, Hutchinson P, Holdsworth SR, Morand EF. 1997. Antiinflammatory effect of lipocortin 1 in experimental arthritis. Inflammation 21: 583-596.
  20. Schalkwijk J, Joosten LA, van den Berg WB, van Wyk JJ, van de Putte LB. 1989. Insulin-like growth factor stimulation of chondrocyte proteoglycan synthesis by human synovial fluid. Arthritis Rheum 32: 66-71.
  21. Goldenberg MM. 1999. Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis. Clin Ther 21: 1497-1513.
  22. Koo HJ, Sohn EH, Pyo S, Woo HG, Park DW, Ham YM, Jang SA, Park SY, Kang SC. 2015. An ethanol root extract of Cynanchum wilfordii containing acetophenones suppresses the expression of VCAM-1 and ICAM-1 in TNF-$TNF-{\alpha}$-stimulated human aortic smooth muscle cells through the $NF-{\kappa}B$ pathway. Int J Mol Med 35: 915-924.
  23. Yang SB, Lee SM, Park JH, Lee TH, Baek NI, Park HJ, Lee H, Kim J. 2014. Cynandione A from Cynanchum wilfordii attenuates the production of inflammatory mediators in LPS-induced BV-2 microglial cells via $NF-{\kappa}B$ inactivation. Biol Pharm Bull 37: 1390-1396.
  24. Shang X, Wang J, Li M, Miao X, Pan H, Yang Y, Wang Y. 2011. Antinociceptive and anti-inflammatory activities of Phlomis umbrosa Turcz extract. Fitoterapia 82: 716-721.
  25. Kim JH, Jeong JH, Jeon ST, Kim H, Ock J, Suk K, Kim SI, Song KS, Lee WH. 2006. Decursin inhibits induction of inflammatory mediators by blocking nuclear $factor-{\kappa}B$ activation in macrophages. Mol Pharmacol 69: 1783-1789.
  26. Rim HK, Cho W, Sung SH, Lee KT. 2016. Nodakenin suppresses lipopolysaccharide-induced inflammatory responses in macrophage cells by inhibiting tumor necrosis factor receptor-associated factor 6 and nuclear $factor-{\kappa}B$ pathways and protects mice from lethal endotoxin shock. J Pharmacol Exp Ther 342: 654-664.

Cited by

  1. Anti-Inflammatory Effects of a Stauntonia hexaphylla Fruit Extract in Lipopolysaccharide-Activated RAW-264.7 Macrophages and Rats by Carrageenan-Induced Hind Paw Swelling vol.10, pp.1, 2018,